Mylan Pharmaceuticals Private Limited, an arm of the US-based Mylan N.V. has launched Gilead Sciences’ Sovaldi (sofosbuvir 400mg tablets) in India.
Sovaldi is indicated for the treatment of chronic hepatitis C infection, a blood-borne infectious disease, as a component of a combination antiviral treatment regimen. It is estimated that approximately 12 million people are chronically infected with hepatitis C in India.
“Mylan has a long-standing history of partnering with Gilead to tackle key public health issues in India and around the world. We are proud to continue our work together with the launch of Sovaldi as it supports our joint commitment to meeting the unmet medical needs of patients in India,’’ Mylan President Rajiv Malik said in a release issued here on Monday.
``Today marks an important milestone in Gilead’s ongoing effort to make its hepatitis C medicines accessible to as many patients, in as many places, as quickly as possible,” said Gregg Alton, Executive Vice President, Corporate and Medical Affairs, Gilead Sciences.
Sovaldi is sold by Mylan’s dedicated sales force as part of its Hepato Care segment. In February 2015, Gilead appointed Mylan as its exclusive distributor of Sovaldi in India.